PP1493
AXP000229.1 · Phage therapy
- Platform
- single phage, solution for injection
- Originator
- Pherecydes Pharma
- Sponsor
- Phaxiam Therapeutics
Names
| Name | Type | Source |
|---|---|---|
| PP1493 | preferred name, code | curator, curator |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Staphylococcus aureus bacteriophage
- Replication
- replicating
- Route
- intravenous, inhaled
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06605651 | Proof of Concept Study to Assess Safety and Efficacy of Phage Therapy in Hip or Knee Prosthetic Joint Infections Due to Staphylococcus Aureus Treated by DAIR. | Not yet recruiting | Phase 2 | 2026-07 | 2028-03 | 100 | Hip Prosthesis Infection; Knee Prosthesis Infection |
Recent changes
No changes recorded in its trials yet.
Notes
Anti-Staphylococcus aureus phage, supplied as a solution for injection and used with PP1815 under French compassionate access (ANSM) for bone and joint infection, intravenously for bacteraemia and endocarditis and by aerosol for purulent bronchopathy, and in the PhagoDAIR I trial NCT05369104 (EudraCT 2021-004469-11) and PhagoDAIR II NCT06605651. Entered separately from PP1815 because the two are separate injectable products that a phagogram can find active singly or together.
How to cite
PP1493 (AXP000229.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000229.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.